Quarterly report · Q1
7733.TEDINET S100OX7K
Period2022-04-01 → 2022-06-30
Filed2022-08-09
StandardIFRS
ConsolidatedYes
Data checks10 of 10 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥214.1bn | 2022-04-01 → 2022-06-30 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥868.9bn | 2021-04-01 → 2022-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥191.5bn | 2021-04-01 → 2021-06-30 | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥40.8bn | 2022-04-01 → 2022-06-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥27.6bn | 2021-04-01 → 2021-06-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥38.2bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥149.9bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥27.0bn | 2021-04-01 → 2021-06-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥24.9bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥115.7bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥18.7bn | 2021-04-01 → 2021-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥24.9bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss IFRS |
| Net income | ¥18.7bn | 2021-04-01 → 2021-06-30 | Cons. | Profit loss IFRS |
| Total assets | ¥1.43T | at 2022-06-30 | Cons. | Assets IFRS |
| Total assets | ¥1.36T | at 2022-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.14T | at 2021-06-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥851.3bn | at 2022-06-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥846.6bn | at 2022-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥582.2bn | at 2022-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥511.4bn | at 2022-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥401.4bn | at 2021-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥395.5bn | at 2021-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥581.1bn | at 2022-06-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥510.2bn | at 2022-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥400.4bn | at 2021-06-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥286.4bn | at 2022-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥302.6bn | at 2022-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥168.7bn | at 2021-06-30 | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | −¥26.9bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥169.7bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥23.7bn | 2021-04-01 → 2021-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | ¥5.2bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥71.0bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥33.5bn | 2021-04-01 → 2021-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥21.7bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥40.7bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥39.0bn | 2021-04-01 → 2021-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥19.53 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥90.22 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥14.54 | 2021-04-01 → 2021-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥19.52 | 2022-04-01 → 2022-06-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥90.17 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥14.53 | 2021-04-01 → 2021-06-30 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 40.5% | at 2022-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 37.6% | at 2022-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 35.0% | at 2021-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 12
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-06-30 | ¥4.5bn |
| jpcrp040300-q1r_E02272-000Endoscopic Solutionsreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥24.8bn |
| jpcrp040300-q1r_E02272-000Otherreportable segment | segment profit | 2022-04-01 → 2022-06-30 | −¥298m |
| jpcrp040300-q1r_E02272-000Scientific Solutionsreportable segment | segment profit | 2022-04-01 → 2022-06-30 | −¥1.6bn |
| jpcrp040300-q1r_E02272-000Therapeutic Solutionsreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥13.4bn |
| —segment total | segment profit | 2022-04-01 → 2022-06-30 | ¥36.3bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-06-30 | −¥10.4bn |
| jpcrp040300-q1r_E02272-000Endoscopic Solutionsreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥22.7bn |
| jpcrp040300-q1r_E02272-000Otherreportable segment | segment profit | 2021-04-01 → 2021-06-30 | −¥565m |
| jpcrp040300-q1r_E02272-000Scientific Solutionsreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥1.9bn |
| jpcrp040300-q1r_E02272-000Therapeutic Solutionsreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥14.1bn |
| —segment total | segment profit | 2021-04-01 → 2021-06-30 | ¥38.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 615
| Item | Context | Value | Unit |
|---|---|---|---|
| Share of profit loss of investments accounted for using equity method IFRS | Prior1YTDDuration_jpcrp040300-q1r_E02272-000EndoscopicSolutionsReportableSegmentMember | 83000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | Prior1YTDDuration_jpcrp040300-q1r_E02272-000TherapeuticSolutionsReportableSegmentMember | -48000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | Prior1YTDDuration_jpcrp040300-q1r_E02272-000ScientificSolutionsReportableSegmentMember | － | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | Prior1YTDDuration_jpcrp040300-q1r_E02272-000OtherReportableSegmentMember | － | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | Prior1YTDDuration_ReportableSegmentsMember | 35000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | Prior1YTDDuration | 35000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1YTDDuration_jpcrp040300-q1r_E02272-000EndoscopicSolutionsReportableSegmentMember | 7983000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1YTDDuration_jpcrp040300-q1r_E02272-000TherapeuticSolutionsReportableSegmentMember | 3877000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1YTDDuration_jpcrp040300-q1r_E02272-000ScientificSolutionsReportableSegmentMember | 1716000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1YTDDuration_jpcrp040300-q1r_E02272-000OtherReportableSegmentMember | 385000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1YTDDuration_ReportableSegmentsMember | 13961000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1YTDDuration_ReconcilingItemsMember | 1778000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1YTDDuration | 15739000000 | JPY |
| Impairment losses pl IFRS | Prior1YTDDuration_jpcrp040300-q1r_E02272-000EndoscopicSolutionsReportableSegmentMember | 1659000000 | JPY |
| Impairment losses pl IFRS | Prior1YTDDuration_jpcrp040300-q1r_E02272-000TherapeuticSolutionsReportableSegmentMember | － | JPY |
| Impairment losses pl IFRS | Prior1YTDDuration_jpcrp040300-q1r_E02272-000ScientificSolutionsReportableSegmentMember | － | JPY |
| Impairment losses pl IFRS | Prior1YTDDuration_jpcrp040300-q1r_E02272-000OtherReportableSegmentMember | － | JPY |
| Impairment losses pl IFRS | Prior1YTDDuration_ReportableSegmentsMember | 1659000000 | JPY |
| Impairment losses pl IFRS | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Impairment losses pl IFRS | Prior1YTDDuration | 1659000000 | JPY |
| Sales to external customers IFRS | CurrentYTDDuration_jpcrp040300-q1r_E02272-000EndoscopicSolutionsReportableSegmentMember | 116857000000 | JPY |
| Sales to external customers IFRS | CurrentYTDDuration_jpcrp040300-q1r_E02272-000TherapeuticSolutionsReportableSegmentMember | 72365000000 | JPY |
| Sales to external customers IFRS | CurrentYTDDuration_jpcrp040300-q1r_E02272-000ScientificSolutionsReportableSegmentMember | 21925000000 | JPY |
| Sales to external customers IFRS | CurrentYTDDuration_jpcrp040300-q1r_E02272-000OtherReportableSegmentMember | 2913000000 | JPY |
| Sales to external customers IFRS | CurrentYTDDuration_ReportableSegmentsMember | 214060000000 | JPY |
| Sales to external customers IFRS | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Sales to external customers IFRS | CurrentYTDDuration | 214060000000 | JPY |
| Intersegment sales IFRS | CurrentYTDDuration_jpcrp040300-q1r_E02272-000EndoscopicSolutionsReportableSegmentMember | － | JPY |
| Intersegment sales IFRS | CurrentYTDDuration_jpcrp040300-q1r_E02272-000TherapeuticSolutionsReportableSegmentMember | － | JPY |
| Intersegment sales IFRS | CurrentYTDDuration_jpcrp040300-q1r_E02272-000ScientificSolutionsReportableSegmentMember | － | JPY |
| Intersegment sales IFRS | CurrentYTDDuration_jpcrp040300-q1r_E02272-000OtherReportableSegmentMember | 102000000 | JPY |
| Intersegment sales IFRS | CurrentYTDDuration_ReportableSegmentsMember | 102000000 | JPY |
| Intersegment sales IFRS | CurrentYTDDuration_ReconcilingItemsMember | -102000000 | JPY |
| Intersegment sales IFRS | CurrentYTDDuration | － | JPY |
| Net sales IFRS | CurrentYTDDuration_jpcrp040300-q1r_E02272-000EndoscopicSolutionsReportableSegmentMember | 116857000000 | JPY |
| Net sales IFRS | CurrentYTDDuration_jpcrp040300-q1r_E02272-000TherapeuticSolutionsReportableSegmentMember | 72365000000 | JPY |
| Net sales IFRS | CurrentYTDDuration_jpcrp040300-q1r_E02272-000ScientificSolutionsReportableSegmentMember | 21925000000 | JPY |
| Net sales IFRS | CurrentYTDDuration_jpcrp040300-q1r_E02272-000OtherReportableSegmentMember | 3015000000 | JPY |
| Net sales IFRS | CurrentYTDDuration_ReportableSegmentsMember | 214162000000 | JPY |
| Net sales IFRS | CurrentYTDDuration_ReconcilingItemsMember | -102000000 | JPY |
| Net sales IFRS | CurrentYTDDuration | 214060000000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration_jpcrp040300-q1r_E02272-000EndoscopicSolutionsReportableSegmentMember | 24834000000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration_jpcrp040300-q1r_E02272-000TherapeuticSolutionsReportableSegmentMember | 13357000000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration_jpcrp040300-q1r_E02272-000ScientificSolutionsReportableSegmentMember | -1609000000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration_jpcrp040300-q1r_E02272-000OtherReportableSegmentMember | -298000000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration_ReportableSegmentsMember | 36284000000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration_ReconcilingItemsMember | 4492000000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration | 40776000000 | JPY |
| Finance income IFRS | CurrentYTDDuration | 722000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 10 of 10 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |